Our results revealed that the level of BCR-ABL P210 clearly increased after adding the SARS-CoV-2 pseudovirus, which was consistent with the phenomenon observed in CML patients infected with the COVID-19 (Figure 5). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.